Evidence map›Paper›PMID 32830462›Full record

Trial reportAnnals of clinical and translational neurology2020

Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS.

Priscilla Bäcker-Koduah, Carmen Infante-Duarte, Federico Ivaldi, Antonio Uccelli, Judith Bellmann-Strobl, Klaus-Dieter Wernecke, Michael Sy, Michael Demetriou, Jan Dörr, Friedemann Paul and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01440062 (Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01440062 phase2terminatednot on this map

Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis

TypeinterventionalSponsorCharite University, Berlin, GermanyRan2011 to 2017Enrolled55ConditionsMultiple SclerosisArmsVerum arm receiving Vitamin D oil, low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Priscilla Bäcker-KoduahCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.ORCID 0000-0002-9751-3464
Carmen Infante-DuarteCharité - Universitätsmedizin Berlin, Institute for Medical Immunology, Berlin, Germany.
Federico IvaldiDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, CEBR University of Genoa, Genoa, Italy.
Antonio UccelliDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, CEBR University of Genoa, Genoa, Italy.
Judith Bellmann-StroblCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.
Klaus-Dieter WerneckeCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.
Michael SyDepartment of Neurology, University of California, Irvine, CA, USA.
Michael DemetriouDepartment of Neurology, University of California, Irvine, CA, USA.
Jan DörrCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.
Friedemann PaulCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.
Alexander Ulrich BrandtCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.ORCID 0000-0002-9768-014X
Max Delbrück Center · DEUniversity of California, Irvine · USHumboldt-Universität zu Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEOspedale Policlinico San Martino · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect of cholecalciferol (vitamin D3) supplementation on peripheral immune cell frequency and N-glycan branching in patients with relapsing-remitting multiple sclerosis (RRMS).

methodsExploratory analysis of high-dose (20 400 IU) and low-dose (400 IU) vitamin D3 supplementation taken every other day of an 18-month randomized controlled clinical trial including 38 RRMS patients on stable immunomodulatory therapy (NCT01440062). We investigated cholecalciferol treatment effects on N-glycan branching using L-PHA stain (phaseolus vulgaris leukoagglutinin) at 6 months and frequencies of T-, B-, and NK-cell subpopulations at 12 months with flow cytometry.

resultsHigh-dose supplementation did not change CD3+ T cell subsets, CD19+ B cells subsets, and NK cells frequencies, except for CD8+ T regulatory cells, which were reduced in the low-dose arm compared to the high-dose arm at 12 months. High-dose supplementation decreased N-glycan branching on T and NK cells, measured as L-PHA mean fluorescence intensity (MFI). A reduction of N-glycan branching in B cells was not significant. In contrast, low-dose supplementation did not affect N-glycan branching. Changes in N-glycan branching did not correlate with cell frequencies.

interpretationImmunomodulatory effect of vitamin D may involve regulation of N-glycan branching in vivo. Vitamin D3 supplementation did at large not affect the frequencies of peripheral immune cells.

Indexed as

Dietary SupplementsAdultB-Lymphocyte SubsetsCholecalciferolFemaleHumansImmunologic FactorsKiller Cells, NaturalMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingPolysaccharidesT-Lymphocyte SubsetsTreatment OutcomeCholecalciferolImmunologic FactorsPolysaccharides

Identifiers

PMID32830462
PMCPMC7480923
OpenAlexW3080187250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.